MedTrace Logo

Copeptin in Outcome Prediction of an Acute Psychotic Episode

NCT03235908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2020-09-21

No results posted yet for this study

Summary

An acute psychotic episode is a severe psychiatric syndrome which might occur in different psychiatric diagnoses.

The outcome prediction of relapse rate of a psychotic episode within a certain time frame is difficult and depends on many factors. More and better predictors are required to improve the outcome prediction in order to adjust therapy and follow-up if patients suffer from this acute disease.

Copeptin, a surrogate marker for vasopressin, has been proven helpful in the prediction of the outcome in serious somatic diseases. Additionally, a rise of copeptin due to psychological stress was shown.

The aim of this study is to investigate the association of the neuroendocrine biomarker copeptin and the prediction of the onset of psychotic episode within one year.

Conditions

  • Acute Psychotic Episode
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Affective Disorder
  • Bipolar Disorder

Interventions

OTHER

Observation only

Observation only

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Mirjam Christ-Crain, MD-PhD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235908 on ClinicalTrials.gov